Brandon Li talks with Matt Leoni—former Senior VP of Global Clinical Development at Cerevel and now Chief Medical Officer at Merida Biosciences. Matt shares his journey from medical school to leading late-stage drug development in neuroscience. He discusses the unique challenges of neuro drug development, from the subjectivity of endpoints and high placebo response rates to the operational hurdles of large-scale trials. Matt offers candid insights into why promising drugs sometimes fail, the limitations of current measures, and where innovation is most needed. The conversation explores disease-modifying therapies, advances in Parkinson’s and schizophrenia research, the promise and pitfalls of psychedelics and psychoplastogens, and his vision for a more risk-tolerant industry that fosters breakthrough discoveries.
Matthew Leoni 0:00 Everything I I thought it would be, but you have to love, you know, ambiguity and problem solving and all these other kind of really cool interesting theories and dealing with risk and stuff like that.
Brandon Li 0:24 Well, Matt, uh, thank you so much for taking the time to have this conversation. I really appreciate it.
Matthew Leoni 0:29 Sure. Happy to be here, Brandon.
Brandon Li 0:31 Yeah. Um, for the audience, uh, Mats is the chief medical officer of a yet undisclosed, uh, new Third Rock, um, Ventures company. Um, he was also previously the, uh, senior VP of global clinical development over at Ceravell famously, um, recent recently acquired by AbbVie and, um, had a, uh, a recent hit in in Parkinson's as well. So I'm excited today to jump into everything, uh, neuroscience and, uh, the kind of feature of the space.
Matthew Leoni 0:56 Me too.
Brandon Li 0:58 Um, well, Matt, may maybe just, uh, for me, uh, if you could give me a a thumbnail sketch of your career and and how how you kind of ended up, um, doing the work that you do. y to jump into everything, uh, neuroscience and, uh, the kind of feature of the space.
Matthew Leoni 0:56 Me too.
Brandon Li 0:58 Um, well, Matt, may maybe just, uh, for me, uh, if you could give me a a thumbnail sketch of your career and and how how you kind of ended up, um, doing the work that you do.
Matthew Leoni 1:06 Sure. Yeah. Um, absolutely. So I, um, I've pretty much been an industry guy for most of my career. I didn't spend a lot of time in clinical, so I went to med school at Penn, uh, UPenn. Um, also got a business theory in in Philadelphia while I was there. And then, um, was focusing in, uh, pathology and was gonna back they're gonna be a practicing pathologist and just realized kinda what that life is gonna be and, um, just realized I'd there was other things I wanted to do. And so so I kinda really went right to industry, um, and started out. And since then, it's been seventeen, eighteen years, um, since I made that jump. Um, my wife as well, she's also does the same thing I do. She does the clinical development in the oncology space, so we kinda made the jump at the same time. She's also a physician. Um, Yeah. And so it started out the and I've been all over the place. I started in derm, um, got a couple of drugs approved in the dermatology space, and that's how I got exposed to kinda immuno. Then I kinda jumped over immuno slash neuro, um, was, um, part of some of the drug development and the approvals in the MS space at Novartis. Um, I worked on some of their stuff. Uh, and then I was prior to Cervel, I was at Otsuka. Um, and that was really where I got more into neuropsych, uh, and then the neuroside, and that's where I met Ray Sanchez, uh, who was at the time. He was the head of, uh, the development there. So I was working for him and working across our portfolio. We're salty and some of the some of the newer stuff that's getting approved, uh, we we worked on before we left. And then Ray went to, um, Sarabelle was tapped to to lead Sarabelle, which was the formation of, um, basically, Pfizer's neuropsych pipeline, their neuro pipeline, and and a bunch of the investor, uh, financing. Um, so Ray took over CMO, asked to ask me. He, you you know, found a way found a way to work together again and to to come over and and join him in the development there. Um, so that was the last five years and a lot of hard work in terms of the Parkinson's space, epilepsy, obviously, schizophrenia. Um, had a bit of a letdown recently in the schizophrenia side with the with the asset, and, uh, we can certainly talk about that more and kind of the implications of that. Um, but, yeah, we we were acquired by Avi recently for all those assets. And, um, um, from that, I I took on a new role, as you said, as a as a chief medical officer now myself and kind of gonna have the chance to build my own company, um, bring in my own team and stuff. So, hopefully, it'll be it'll be disclosed soon, maybe, hopefully, in the new year and stuff like that. But I'm, uh, I'm obviously really excited about it. But, yeah, happy to, uh, to dig in and talk about, uh, neuro and all the happenings over the last couple of years, the last couple of months, and and, um, see where it takes us. , it'll be it'll be disclosed soon, maybe, hopefully, in the new year and stuff like that. But I'm, uh, I'm obviously really excited about it. But, yeah, happy to, uh, to dig in and talk about, uh, neuro and all the happenings over the last couple of years, the last couple of months, and and, um, see where it takes us.
Brandon Li 3:32 Yeah. Absolutely. And and just before we dive into, uh, to neuro, um, what's it like at the dinner table? Are are your wife and, uh, are are you and your wife just talking about, uh, clinical development over, uh, over dinner?
Matthew Leoni 3:43 Yeah. And it's about it's like this competition of, like, I got this approval. I'm doing this. Well, now I'm the chief medical. Well, I'm the chief I'm the head of development, and I'm the head but it's it's been good. She started out in drug safety and just kind of evolved into, um, the oncology space, and she's she's gotten she's pretty well known. She's got a fair amount of drugs approved as well, and, um, she's working at a really nice place also here in in Boston. So it's we keep you out of each other's spaces, so it's not like we're not competing and we're not going to the same conferences and stuff like that. But it's nice to have somebody who knows drug safety stuff from, like, a mall. Um, if I have a patient that, like, this is, um, what would you do? And this kind of stuff. And the same thing for for us with neuro. So it's been it's been a nice collaboration, but, yeah, it gets a little competitive sometime.
Brandon Li 4:23 Yeah. Well, I know you have kids, so, um, um, maybe they steer into, uh, uh, into the industry or maybe they stay, uh, stay very widely away from it. of stuff. And the same thing for for us with neuro. So it's been it's been a nice collaboration, but, yeah, it gets a little competitive sometime. Yeah. Well, I know you have kids, so, um, um, maybe they steer into, uh, uh, into the industry or maybe they stay, uh, stay very widely away from it.
Matthew Leoni 4:32 Uh, I I mean, there's different ways to go. Definitely ways to to go in the industry. I mean, getting that MD is med school is brutal, and so is resident side and stuff. And med medical practice right now is challenging. But that's why I think you see it becoming a this third pathway. Like, so when we did it, it wasn't that common. It was this sort of unspoken third pathway still. But now, you know, those guys going and getting MDs and and MBAs and stuff and just going right to McKinsey and going right into the venture side and things like that. And so it's, um, coming much more common because it's it's really a a third career trajectory now, which when when we did it in, you know, in, you know, the early two thousands, it was still a little um, it wasn't the thing they talk about it, like, in med school and stuff, but here's another trajectory gone. But it's it's absolutely a a great career choice for, um, you you have to break the the mode. And my wife and I were the same way where it's like, you have to like ambiguity, and you have to like uncertainty. And that like, as physicians, you're trained not to do that. You're trained to, like, put things in a box and classify them and because you're trying to eliminate medical errors and and obviously people's last word stick. Um, and then the drug development space, we get to work with patients, you know, at at more of a distance, but at a larger sort of proportion. But it is much more ambiguous. Things aren't gonna work, and you always have to be ready to pivot. And every day is slightly different. And so you're you're you're trying to innovate and do things differently, which is not necessarily in medicine. There are ways that they're trying to do it, but you also like, your day to day is trying to keep things in a very circumspect way controlled. Um, and so that uncertainty doesn't sort of sit well sometimes with a physician's mode. And so some physicians hate industry and leave, um, because of that. And then, um, some of us love and flourish in it, and it just happens to be a thing we like doing. So
Brandon Li 6:09 Yeah. Um, you know, this isn't a career podcast, but maybe, uh, I'm too curious to ask. Like, if if somebody is a, um, training, uh, physician and has an inkling that maybe there's something, uh, they can try, like, what what advice do you have for them? And, uh, how how how could they think about derisking it maybe and considering it? w, this isn't a career podcast, but maybe, uh, I'm too curious to ask. Like, if if somebody is a, um, training, uh, physician and has an inkling that maybe there's something, uh, they can try, like, what what advice do you have for them? And, uh, how how how could they think about derisking it maybe and considering it?
Matthew Leoni 6:26 Yeah. I mean, I think it's you know, if you're in medicine and you it depends on what your what your flavor is. It it like, what is what's driving you? If you really like the patient interaction and you really like sort of that day to day sort of engagement with people and the patients and stuff, and that's what drove you, and that drives a lot of folks to medicine, then, you know, it may not be a great career choice because it it's it is more far removed, and it's more of that sort of larger the larger doing good at a larger level that you're gonna sort of create drugs for unmet needs and and to help people. Um, and it does it is a business. It is a for profit industry, and it it's all those things that you have to realize that it's not just a scientific experiment that you have to you have all different stakeholders that are involved, but that aren't involved when you're talking about just patient care. So, I mean, if you have those instincts that it's, you know, you wanna make these sort of larger contributions, you really wanna make a a dent from a scientific perspective and sort of have large impacts, which I think even in academic medicine is very hard to do on a large scale. Um, and you enjoy sort of changing dynamics and and different competing, you know, um, stakeholders and and commercial interest and other things like that that you're trying to balancing all these things and walking a tightrope. And and it's a strategy game as well. It's a if you like that kind of mindset of sort of a bit of game theory and a little bit other things about how you engage with health authorities and how you derisk programs and stuff, um, always keep it in the back of your mind. And I think the easy way for if you're sort of if you know that that's what you wanna do, then I would say don't waste time and just go do it. Find a find a way in. Um, and there's all different kinds of training programs, and they're they're looking for clinicians are, um, are always welcome in the industry even even ones with limited experience. If you're kind of straddling on, I'm not sure if I wanna do that. The easy way is is that I think we see a lot of physicians come from it is get involved in the clinical trials, um, even when you're a resident, um, and or early on in your career and and really sort of engage on that. And you can really get a feel for what it's like in running trials and being a part of it and designing and the things that happen. And if you really feel like this is what it will always you always have that out then if you say, like, hey. I'm a lot of the clinicians that come to come to Insure are burnt from from the the the grind of the business side of of just running sort of the the mill of of of clinical practice and stuff. So, um, that would be, like, my basic career thing is is if if you know in your head, like, you're not I I look. I was gonna be a pathologist. I didn't need the patient contact. I was not that was not high on my list. I'd love more of the the science and the strategy, and this seemed like a great way to be able to kinda do that, the big explore the business side as as well. And it and it's everything I I thought it would be, but you have to love, you know, ambiguity and problem solving and all these other kind of really cool interesting theories and dealing with risk and stuff like that. And if that feels right to you, start early, you know, get, like, get involved even when you're a resident, like, with a with a the drug company do internships and stuff like that with with drug codes about how do you do clinical development, how do you think about, you know, clinical regulatory strategy and stuff like that, and get some exposure early on. Those weren't really options when I was coming up. They they really want those opportunities, but there's many more so now just because I think it is a career pathway for physicians that's very clear, um, even getting in on things like the venture side and the investment side of that. There's more opportunities and just take advantage and explore it. You know? ming up. They they really want those opportunities, but there's many more so now just because I think it is a career pathway for physicians that's very clear, um, even getting in on things like the venture side and the investment side of that. There's more opportunities and just take advantage and explore it. You know?
Brandon Li 9:35 Yeah. Absolutely. And, um, may maybe this is the right jumping off point. Um, I'd love to hear just, like, as you think about kind of the clinical development landscape, uh, specifically in neuro, uh, maybe paint us
Matthew Leoni 9:47 a picture of, like, how you think
Brandon Li 9:48 about that landscape today, um, and then I'd love to kind of jump into, um, what excites you the most. ove to hear just, like, as you think about kind of the clinical development landscape, uh, specifically in neuro, uh, maybe paint us
Matthew Leoni 9:47 a picture of, like, how you think
Brandon Li 9:48 about that landscape today, um, and then I'd love to kind of jump into, um, what excites you the most.
Matthew Leoni 9:53 Sure. Um, I mean, neuro's always been an it it sound like a broken record, but, like, neuro is one of the hardest things to do in terms of drug development in my and I've done it, like, across the experiment and maybe going back to the comparison with my wife. Like, I'm not gonna say oncology is easy, but from a true, like, risk and the endpoint perspective, it's it's very circumspect in how they and the risk that they deal with and kind of the endpoints that they're joined with and and and challenges. Neuro is really hard just because, again, it's so subjective. You're talking about how people feel and how they feel kind of on a day. There's not these really good objective measures of a lot of these things, especially in neuropsych when you're talking about, you know, a clinician's interpretation of what a patient is thinking or how they're acting and stuff. It's just all these things that are subject to variability. So I think that breeds a certain type of, you know, uncertainty and a certain type of trepidation in terms of, you know, trial failure per, uh, the ability for trials to fail and even good drugs kind of failing because, you know, trials aren't executed right or just because of the the nature of the beast and the variance. And I think it's that's not as the that's not as the that's not the case and maybe some other therapeutic indications wherein the endpoints and the execution is easier or it's it there's just they don't have to deal with so many uncertainties and unknowns. Um, so I think because of that, there's always this kind of skepticism in neuro about, like, how hard is get drugs approved. And it is. And you can look across, like, it's one of the highest failure rates of all the therapeutic areas. And so it's not for the for the faint of heart. And then it's also one of these things because of the subjectiveness of our endpoints. Placebo response is such an issue for us in terms of these measures and collapsing trials. And we just kinda dealt with that with, you know, the what happened with, um, imraclidine and and some of the other schizophrenia programs. But, you know, major depressive disorder, it's across the board. It's just it was wake, like, incrementally every year. It's getting harder and harder to do these execute these studies with good data to just to separate from placebo because twenty five years ago, there weren't all these trials that were ongoing. And so it was these whether you say the patient population were fresher or they were cleaner or whatever, um, whether we've just saturated them or we've recycled too many patients or whatever it is. But, like, year over year, it just keeps getting more and, like, you can look at all the metadata that shows the trajectory of just placebo response and variability and stuff is just getting harder and harder to show drug effects in an experimental design. I mean, it's what drug trials are, an experiment. It's a hypothesis test, and it's a controlled environment, and you're trying to show you know, remove all the as much of the variables as you can and show that, you know, the drug actually objectively is safe, and it's and it's efficacious. Um, and that just keeps getting harder. Um, and I think the the degree of difficulty because of just the nature of the beast and competition and how many trials are out there and and all that kind of stuff, we're not keeping pace probably with that with our measures and, like, the sensitivity of the measures that we're using or the or the types of measures we can use to get at these endpoints or how we're conducting the trials and accessing different new newer patient populations and stuff and not recycling things and stuff like that. I don't know that we're keeping pace, but I think that's what we have to do from my perspective. Like, the landscape is really I think it's struggling right now. Like, before I had this renaissance in neuro because we had a couple of big wins, and it's always, like, the right the pencil always swings and, like, then but that was coming off of, like, this huge downswing because of all the failures of the beta amyloid drugs. But now one or two of them have kinda worked, and now some of the neuropsych stuff hits. But now you see, like, you take a big hit, like, you see you crash back to reality. Um, the synovium program, the tar ones collapsed. And then now everybody was into the muscarinics, and now it's like now they're questioning, yes. Um, BMS, Karuna is getting approved, but, um, you know, look, drugs can fail, and it brings you back to reality. And then it reminds you that these these are not slam dogs. Just because you have a great molecule does not mean you can get a great outcome. Um, and I think that's just on all of us that that are in the business and in the industry to, like, keep reminding ourselves and looking at that. Like, you can't get stagnant with sort of innovating in how you're gonna, you know, conduct trials, how you're gonna explore trials and whatever. Um, and you're fighting kind of against that regulatory upswing of, like, what, you know, what the FDA wants in balancing all these things. So I think it's it's, um, it's an evolving landscape. Uh, I've been pleased with what we've seen come along in neuron. I think it'll it'll keep going despite some of the the recent hits. But, I mean, a couple more failures, and then you'll see investors pull back. And I think it'll but like everything else, I think it's cyclical. Um, and we just have to be mindful of and respect sort of the the drug gods as as it were as, like, we kinda call them the drug gods can be cruel, and they will you know, they they you have to remember, you have to have a lot of humility when you're doing this, and you have to have a lot of, um, respect for that and and be very, very cognizant of how you do that trials and and knowing, you know, know what you don't know. Yeah. So, um, but I think it's it's certainly encouraging. I again, some of the bigger wins with the bigger investments, I think you're gonna see some of that stuff, um, on the neuro side. And then on the on the psychiatric side, um, I don't think in in interest is waning. I think those people are gonna keep trying to figure out more stuff. So it's certainly, like, picking up, but I'm I'm hopeful that we see a couple of more wins before we see a couple of big big hits that it keeps that momentum building because I think it's sort of been at a tenuous spot right now. n interest is waning. I think those people are gonna keep trying to figure out more stuff. So it's certainly, like, picking up, but I'm I'm hopeful that we see a couple of more wins before we see a couple of big big hits that it keeps that momentum building because I think it's sort of been at a tenuous spot right now.
Brandon Li 15:24 Yeah. Oh, you you've you've painted, like, uh, an interesting landscape as to the challenges in the development, everything from the subjectivity of the scoring to the, uh, potential, like, oversaturated kind of like, um, uh, like patient landscape. Um, what what do you think we should be doing differently, um, in the in the pace of this landscape? Right? Uh, it's kind of the game on the board now. Right? So, um, what will he be doing about from the subjectivity of the scoring to the, uh, potential, like, oversaturated kind of like, um, uh, like patient landscape. Um, what what do you think we should be doing differently, um, in the in the pace of this landscape? Right? Uh, it's kind of the game on the board now. Right? So, um, what will he be doing about
Matthew Leoni 15:49 that? It's a great I mean, it's a great question because it's like, if I knew the answer, like, I'd I'd You'd be doing it. Yeah. I'd be doing it, and we would also solve I mean, I think we saw like, again, I don't hold punches on this stuff. Like, I think he saw, like, there's a lot of, like, a lot of consolidation in the last few years, a lot of consolidation, like, the the typical sites that we would use for trials and things like that. Like, you're seeing large conglomerates buying up these these site networks. And so you're seeing this sort of rise of large site networks, which is great. I mean, it's it's a thing because it's, again, inpatient trials, these things are profitable. Um, but, like, then you start seeing quality decline and things like that. So I think we just have to start rethinking a little bit about how we're approaching sort of operationalizing these trials when we need sort of these large patient sample sizes. And, I mean, that's such a loaded question. You can get into so many different things. Like, it means, well, if we're gonna, you know, start doing different things outside of these sites or we're gonna try to sort of crowdsource trials or any of the kind of the the things you think are possible, um, we have to figure out ways we can control variance and endpoints and stuff. So there's always a cost to to something. But I think I think it starts with continuing to sort of engage with the regular regulators to say, like, we wanna push on some newer endpoints and some new sensitive measures, and we have to get away from sort of the old mindset of, like, what constitutes a valuable endpoint. Um, it's kind of like dichotomous with the the agency wants, um, you know, endpoints that are really patient relevant. You know, patient centered drug development, which I totally agree with. But, like, that's completely sort of detached from this notion of, like, all the sort of new advancements in biometric measures and and, you know, wearables and sort of more objective things and thinking about, like, can your heart rate and your, you know, your walking pattern, all things sort of predict your mood or your or to, like, it's sort of you want things that patients say, I feel this. I feel better. It's doing better. And then but those are the things that are probably the most erratic in the sense of, like, as a measure that you're trying to study and sort of all over the place and sort of because it is. It's it's so so the more subjective you get about how do you feel, you know, the more the harder it gets to get, like, a real signal that a drug works and things like that. So I think we're we're struggling with that, but I think if we can find alignment there and start there around, like, let's evolve some new measures that are, you know, that can remove some of this variance that we see that can make them more sensitive, but still show us things that are or at least correlate them to things that are compelling for patients and that are really addressing unmet needs in patients. Like, that's the first step because I think there's a lot of, like, good drugs that we don't have or you just because they die, you never hear about them because they die in sort of the early phases because they can't generate a signal. And it may not be that the drug or the mechanism doesn't work, but maybe it's a too weak and you could improve on it, but they just never see the light of day because we don't have the right tools to maybe look at them in the right way. Um, so I think that's gotta be sort of the push for, you know, the industry to keep to keep working on. And it's hard because the a lot of these things take time, and they take a lot of patience, and they take, um, you know, lots of different types of studies. But, you know, you you try a drug out and it doesn't work out, then it's on to the next one, and you have to work on something that's gonna generate interest and value. And so there's not a lot of room or time to explore things that aren't working. ience, and they take, um, you know, lots of different types of studies. But, you know, you you try a drug out and it doesn't work out, then it's on to the next one, and you have to work on something that's gonna generate interest and value. And so there's not a lot of room or time to explore things that aren't working.
Brandon Li 19:10 So let me, let me be difficult, right? Like whose job is it to develop these measures?
Matthew Leoni 19:17 Well, I mean, this is it's it's it's you would say it's this the sponsors, it's it should be in my purview that we should do that because it will help me develop better drugs. And if I can develop these measures from a proprietary standpoint, it gives me a competitive advantage over my competitors in terms of how I'm gonna look at drugs and things like that. But the time and the effort it takes to develop new measures is much harder, and the the risk of, like, developing something new and having that working than just going back to what works, what's been used for for approval. Uh, and, again, to the point, you know, like, using schizophrenia as a model and so like that, the the pan scale has been used for now decades as an endpoint. And not that it's a bad endpoint. It works, and it's been it's a great measure, but, like, it's got a lot of issues with it. Um, but it's just it's accepted, and it's just like so if it's almost like if it ain't broke, don't fix it. So as a, you know, as a drug developer and I have an asset and I'm being pushed to develop something fast and and, you know, make it make you know, get it as efficiently as I can to to patients, you know, the the extra time it takes to, like, just go off the reservation to develop a new measure and all these kinds of things. I'm not incentivized to do that. I'm incentivized to kind of use what works already and sort of be as efficient and not break the mold. But then in doing that, you know, if my drug fails on the pins, was it is it because of the drug or is it because of that's showing the flaws instead of some of these measures? And this is the the catch 22 is we're not incentivized to go off the reservation when we don't have to. The only time you really get pushed to do it is when you're breaking new ground in a new indication or a new thing where there is no precedent, and there is nothing new. So you're forced to do it, and that's where you see some of the, like, the most innovation. Um, but the thing where there's always a ground, there's always everything on case law already laid down as it were. It's very hard to sort of convince, you know, a board or a bunch of others like, yeah. This is all very standard, and these guys are doing it fast, but I'm just gonna go off and and do this. Um, at at the point in time that usually when you figure out that you should have done that, it's too late.
Brandon Li 21:18 Too late. rd to sort of convince, you know, a board or a bunch of others like, yeah. This is all very standard, and these guys are doing it fast, but I'm just gonna go off and and do this. Um, at at the point in time that usually when you figure out that you should have done that, it's too late. Too late.
Matthew Leoni 21:19 It's too late. You you know, we should we could've tried a different measure. We could've tried something different, um, and pushed it to give ourselves a better chance of success, and we didn't. So a lot of it a lot of ends a lot of ends up happening in academia as opposed to industry, and then you kind of you have the sponsors kind of pirating what's there and then kind of now maybe modifying and and changing and stuff. But there's not a ton, I'd say, on that one. And then because, again, just because of the time it takes, and it's just not as congruent with sort of moving efficiently and evaluating a drug and use the tools that you kinda have and try to use the the measures you have to mitigate you. I mean, that's where a lot of the industry has come come from trying to mitigate placebo response and things like that. It's less about finding new measures, but it's about more, like, how can we mitigate greater variance, and how can we do these things, which is true, and how can we limit placebo response. Um, and and in some ways, we've been effective there, and in other ways, we we aren't, you know, and there's still a lot of limitations and stuff. But that's sort of like developing new tools and new measures. It's it's really more ends up being the province of academia or sort of these consortia, you know, spot you know, the the industry slash academia consortiums kinda working on stuff, um, that really kinda push these things through. But then, you know, a lot of them never see the light of day and never ever really get traction or or need utility, um, or like I said, there's there's a a lot of potential interest in things like EEG, um, and and, um, and even, like, facial expression and also, like, some sleep stuff with respect to, like, schizophrenia, for example. But to get to a place where you're using that to evaluate your drugs as a print endpoint for registration from the pants, like, it'll be decades Because it's just it'll be so incremental because nobody's willing sort of to paradigm shift it because the pants is accepted and they know it works. And, you know, most of the bottleneck a lot of the bottlenecks to throughput are, you know, getting through with the FDA. Well, we know the FDA accepts the pans. We know they accept this, and so I gotta just let's get my drug to work on that, and then I work it. So it's your reverse your retrofitting your drug into fitting into a regulatory pathway as you know it works that way. You know?
Brandon Li 23:24 So it's challenging. It's interesting to hear that, like, you might be, like, retrofitting your drug for a specific score, like like, in the in a world of neuroscience where it is subjective, like, how is that even possible? ting into a regulatory pathway as you know it works that way. You know? So it's challenging. It's interesting to hear that, like, you might be, like, retrofitting your drug for a specific score, like like, in the in a world of neuroscience where it is subjective, like, how is that even possible?
Matthew Leoni 23:39 It's not I mean, it's like I said, if you're making these assumptions, you say, okay. Here's all the historical precedent on what what is clinically relevant on these measures or what it is. So that's I've just set the bar now for my drug. So I have to, like, retrofit my drug into making sure it meets those criteria. And you can say, well, that's good because that sets a bar of, you know, benefit to a patient or things like that that if your drug is falling beneath it. But, you know, is it really exploring all the things that are relevant to the patient? Is it really exploring, and is it really not working? There's lots of different modalities that may be synergistic to helping the patient in terms of other meds that they're on or or the things that you just you're just not able to explore because you can't split those hairs. So it's sort of you're using this broad sword where you would need a scalpel, but you know the broad sword sets a level that it's like, well, I gotta get here. And if I can't get there and and it's just and all these historical drugs have set these precedent of, like, you know but, again, it it like, you can put, uh, you and you get you basically get one shot at it. Right? So you you you retrofit it. You run these big pivotal trials. And if it doesn't work and it's experiment, then you don't know exactly what went wrong. You rarely have a time a chance to go back and try again. Um, but it doesn't mean, you know, that when you ran that experiment that one time that it didn't work, like, there's all these different nuances that contribute to it. We just don't ever have a chance to go back and rehash it to see, like, what real like, if we had a different tool or we had a different measure, would we have found other ways that the drug was beneficial that it would have made sense to bring it forward or or that it was helping patients in a way we just weren't detecting with sort of these tools or did something else to benefit their quality of life? Um, we don't ever have that opportunity. We just chalk it off as, oh, this mechanism doesn't work or, wow, you know, we just really filed these studies or the and then you put it away. Yeah. And that's a lot a lot of what happens. And I think you you see that. And that's why I said, I think there's there's lots of drugs, you know, drugs that never saw the light day in the drug development graveyard that probably shouldn't have been there or maybe didn't need to be there and probably could have benefit patient. We just didn't have the right tools to be able to demonstrate what's needed to be demonstrated so you can obviously meet those those standards of what is safe and what is effective and what will benefit people. probably shouldn't have been there or maybe didn't need to be there and probably could have benefit patient. We just didn't have the right tools to be able to demonstrate what's needed to be demonstrated so you can obviously meet those those standards of what is safe and what is effective and what will benefit people.
Brandon Li 25:48 Totally. So, um, you know, we we've kind of painted a picture of like the, the challenge in the landscape. I'd love to, um, talk about maybe what you're most excited about. Uh, I'm looking at the, the kind of current landscape of neuro.
Matthew Leoni 26:02 Yeah. I mean, I see the it it goes back and forth. I I would love I think we're getting closer and closer now to more definitive disease modifying therapies. Most of my career stuff has been on the symptomatic side. I mean, I've I've played around with with the symptomatic, um, but also in disease monster. But, you know, most of the the failures in Alzheimer's sort of failed people. But I think we're getting
Brandon Li 26:24 What an influencer now? Uh, maybe the definitions around disease modifying, um, symptomatic, and why you're so excited about, uh, DMTs versus, um, versus the lab. Yeah.
Matthew Leoni 26:36 Um, so right. Asymptomatic therapy, meaning, like, you're going in, you're you're addressing a receptor, or you're you're bridging something. You found a way to sort of modify something that's happening as part of the disease course. So a symptom of the disease, and you can make those symptoms better, but you're not actually changing the disease. You're not curing the disease nor are you changing the trajectory of the disease in terms of it's a disease that's neurodegenerative and going to get worse over time. You're not really interdicting there to slow down that progression. You're treating the symptoms as it progresses, and, you know, higher doses could treat the symptoms as they worsen. Um, you know, again, a great example is Parkinson's disease. You know, Parkinson's disease, the standard of care is levodopa. Levodopa treats the symptoms of losing dopaminergic neurons. It doesn't stop you from losing dopaminergic neurons. Then eventually, you get to a place where even the highest levels of levodopa can't help you. Um, so that's versus disease modifying where, you know, with beta amyloid drugs and things like that where you're actually interdicting now in the in the truest sense of disease modifying, you'd say curative. Right? You're you're talking about cures or things like that, and there's some cases in the oncology space in metabolic where you could talk about that. But, um, in the neurospace, we we generally think about it as changing the trajectory or the progression. So if, you know, if normal normally, a patient would digress over a ten year period, maybe it's you're giving them an extra ten years on their progression so they have better quality of life over that entire time course and slowing it. That's how we look at something that's modifying the actual underlying mediology of the disease versus simply treating a symptom that's a manifestation of it. ar period, maybe it's you're giving them an extra ten years on their progression so they have better quality of life over that entire time course and slowing it. That's how we look at something that's modifying the actual underlying mediology of the disease versus simply treating a symptom that's a manifestation of it.
Brandon Li 28:11 And where where would you bid at, like, uh, yeah, or these, uh, disease modifying therapies? Like, where are you most excited to see them? Where are they coming from? ng that's modifying the actual underlying mediology of the disease versus simply treating a symptom that's a manifestation of it. And where where would you bid at, like, uh, yeah, or these, uh, disease modifying therapies? Like, where are you most excited to see them? Where are they coming from?
Matthew Leoni 28:19 I mean, again, if if it's in the neurospace, you know, beta amyloid and stuff has been the tides for Alzheimer's and everything is and but I I did some of the initial I did some initial work on beta amyloid before I went to med school, and and it was more in the head trauma space, but, um, worked with actually in the same cross coordinated with a lab and published with John Turgernalski, who's, like, sort of the godfather of beta amyloid. Um, and he he passed away. But, um, and that was in 1999, and it was like, we still don't know a ton about, like, how it really plays into this pathway and and sort of interdicting with it, um, what it what is it really doing in terms of what's the clinical benefit of doing that we've been chasing as Dragon for so long. But But I think it's just a limitation of of the neurospace of really understanding the complexities pathways. So what's really got me excited is, again, when you start looking at sort of the new tools that we have now and the dawn of sort of these the the new decades that are gonna be ahead of us and sort of the use of AI and the use of sort of these ways of changing and creating new models and drug development about picking new molecules and new entities that can do this stuff. But just even how we understand how things work in a downstream upstream process and sort of how like, the recuity with which you can model these things and happen then. Um, I think we're gonna complete and things like and also, like, CRISPR technology where we're actually, like, we can get to really sort of more precision kind of stuff. I think you're gonna see in the next, you know, ten, twenty, thirty years, like, a new generation of drugs that will be able to interdict in sort of these disease pathway. Because we'll understand what's happening. We'll be able to, you know, have large leaps and bounds in our understanding of just the neural networks that are in play in the human brain and sort of really, like, if you do this, what happens here? We still don't we still don't have a greater understanding of you know, you can put beta amyloid in addition, it kills neurons. And you're like, well, if I stop that, it's good. Right? But it's just there's so many complex things that, like, you are just our basic research hasn't been able to get our hand around. So I think it's it's that. It's it's really my hope and my fingers crossed because I'm an I'm an end of the road guy. Like, I'm a guy that's, like, at late stage, like, you've got something. And so I I look to, like, all of my peers and my colleagues that are really on the discovery side with all the tools that we have in front of us that are so sort of interesting and and nuanced, um, that we're gonna start figuring some of this stuff out on the that We're in, you know, in the more in the immunology space and metabolic space where the pathways and the linkages and the and the core the connections, the correlations are much clearer. Um, and even in even in oncology, we've gotten a much better understanding of of things in terms of pathways and how the immune system interacts with with cancer cells and stuff to really sort of evolve that treatment landscape that you saw from it was sort of that generation of going from I I liken it to the the chemotherapeutics and sort of the the broad sword of of things to immunotherapy and cancers and kind of where we've evolved. Yeah. Cancer is still everywhere, but some of these therapies that have evolved, um, I'm looking for that inflection point for us in the neuro space where we get to enough of an understanding of of the neuropathways and stuff that we can really start producing some targets that can have some real meaningful impact. And, again, it's because it's not just a, like, you know, is this a viable, this molecule or something? It's it's understanding its impact across the landscape of that neural network because beta amyloid, yeah, is in the brain and interdicting going to the but it's just it's one small piece of a larger puzzle that we haven't figured out that you have to address many more pieces in that puzzle till you get really meaningful effect. I think this is what you see with, like, the the even the approvals for the drugs, this sort of question of, like, are they really impacting cognition if it's just a little, like, you we wanna see big leaps and bounds like we've seen in the oncology space, like we've seen in the immunology space. And I think we're getting there. I think we'll get there, but I think that that's the last frontier that that sort of mapping and understanding of not you know, we know the genome now and our immune systems and the complex metabolic process going, but, like, really understanding the real depth of the neural network part of our of our brains and how, like, all of that is interacting and how we can really sort of engage maybe even with therapies, multiple targets in a similar in the same therapeutic to sort of create this constellation of effects that gives you sort of a multiplicative factor. Like, I think we're on the verge of that. I hope we're on the verge of that. The stuff I've seen gives me gives me comfort in terms of just the evolution of the tools we have in terms of AI. And what I've seen on the discovery side with colleagues, um, is very encouraging, um, compared to, I think, the tools that we had. So, hopefully, that's my hope for for the industry. And then until then, I mean, I think we'll make incremental progress on some of these things. You know? We will see some some things that will look you know, will be in that disease modification space. You know? I think there's some interesting spaces. We've made certainly leaps and bounds in sort of the the the the like, in SMA instead of the gene therapies and something like that. And so I think there'll be more evolution on that side of some of the rare diseases, but sort of these large, more population sort of issues around dementia and sort of these larger diseases and diseases of the mind, like, like, um, they aren't necessarily even neurodegenerative, but, like, schizophrenia and major depressive or psychiatry where we can get beyond just treating the symptoms of those diseases. Even though they're not neurodegenerative, they're not necessarily worsening to a place over time. But we just like, we can't crack the code. Yeah. Unlike, like, it's so complex. Whereas, like, again, even in neuro in the neuropsych landscape where you've got neuro like, we know what causes Parkinson's. We don't well, we don't know what caused it, but we know, like, what's happening. We know that, like, these neurons are degenerating, and we know that you don't have dopamine anymore. Like, why that starts to happen with our idiopath or whatever? Like, there's lots of theories. But, like, in schizophrenia, we just don't know. Like, you know the end result that dopamine is messed up, but, like, what are all these genetic components and all these things? And can you get it? Are there places for us to get to, you know, sort of third ever disease modifying treatments for major depressive disorder, for, you know, treatment resistant depression, for schizophrenia, for anxiety. So these things have played, like, so many people, and all we all we can really do now is kinda play around with neurotransmitters and get better at how we sort of attack those neurotransmitters to kind of limit side effect. And that's what you're seeing, like, with, you know, finding new receptors that get it the same way without hitting the old ones that cause side effects or, you know, adding a couple of different things together if you get a better effect. But at the end of the day, we're still just sort of fighting against the tide about whatever your genetics underlying it or whatever else being produced, you're trying to fight against it. And that's sort of the symptomatic role. And there's make no mistake. There's ground to be to be had there. There's lots of unmet need, and there's lots of therapies that I think we can continue to evolve. But to really start seeing some of these big changes, like, on a population level, um, um, that will make real dense in the impact of of patients' lives. I think we're on that cusp of that of seeing that, and I'm hoping it may not start in neuro again. I think you're seeing gonna see more of it in the oncology space and stuff, but but it will migrate as we start to understand more of these sort of these neural connections and and how, like, all these complexities of how psychiatric illness sort of manifests itself and what it's really root causes and and how it's it's going on and and getting to places where we're talking about, you know, steering people or or really being able to treat them, uh, you know, definitively and and things like that. So, um, there's a lot I have a lot of lot of hope for the landscape. manifests itself and what it's really root causes and and how it's it's going on and and getting to places where we're talking about, you know, steering people or or really being able to treat them, uh, you know, definitively and and things like that. So, um, there's a lot I have a lot of lot of hope for the landscape.
Brandon Li 35:36 Are there are there condition areas where you are, um, uh, more um, uh, more excited about? Or are they you feel like we're we're kind of closer to the, uh, the problem's land right now? , definitively and and things like that. So, um, there's a lot I have a lot of lot of hope for the landscape. Are there are there condition areas where you are, um, uh, more um, uh, more excited about? Or are they you feel like we're we're kind of closer to the, uh, the problem's land right now?
Matthew Leoni 35:49 Um, I'd love this. I mean, again, I I think I think on the neuro side, when you look at the neuro I think just because of the nature of those connections and sort of when you're looking at sort of these functional impacts, I think we're at a better place for understanding sort of the basis of cognition. I think there's a lot of good data on and kinda how we interdict there and the and the different mechanisms. So I think but but again, getting at the so treating cognitive decline or cognitive symptoms, but really getting at the reason what's causing it and causing these things. So whether it's you're in Parkinson's or you're in the dementia space of of Alzheimer's or these other things, I think I think we're probably closer there in terms of understanding the etiologies and getting more sort of directed targeted therapies, whether it is even better symptomatics or cognizant, which are the ones we have right now are not good at all, um, or really getting disease modifying. It's unfortunate, but I I think the the complexities of, you know, schizophrenia, bipolar disorder, sort of the the the big the big elements in the psychiatry space. I think there's just a still a lot of them. We don't really understand well the role that neuroinflammation plays. Um, we don't really understand sort of the role that the genetics are playing because it's so varied, and there's so many different external factors and stuff to really get down to. There's no, like, discrete low side we're getting to or, you know, there's Right. So I think it's those are just farther off because I think those are the most comp I mean, either diseases of the no. You know, this isn't we're talking about neuropath is like it's like it's a disease of the mind, of the mood, of the of thing. And, like, this is the most complex of the self of so you're getting into the most esoteric ethereal part of human existence, um, beyond, you know, your circulatory system and your blood cells or whatever. Like, you're getting in terms of how your brain manifests and all these neurons you have manifest in terms of your mood and your emotions and how you experience the world and, like, deficiencies and pathologies in that by that definition, are gonna be the most complex to understand. You know, we can understand, like, things that are killing cells and things that are making cells die in sort of neurodegenerative diseases or neuroinflammatory disease like MS. Like, we know your immune system is acting abnormally, and it's attacking myelin, and we do and we have these things. We know what's kind of there and what's causing. We don't know necessarily why you get it and I don't. But we know once the person that has it, what's happening. Whereas, like, not only do we can't tell who's gonna get schizophrenia and who's not, but, like, even for the people that have it, we still can't really tell you why you have it or why it's doing that. We know your neurotransmitters are messed up and we know what's happening. But I think to me, that's the the biggest gonna be the biggest challenge in in psychiatry. So that's why I said that I've always a badge it's always been a badge of honor to, like, sort of been doing development in that space because it is it is the hardest. Not only is it the hardest disease landscapes to understand and sort of map and model and sort of figure out ways to get at the underlying etiology, finding ways to treat it symptomatically and find a new receptor that will sort of bring dopamine back into balance and things like that. Like, that's we've been able to do that, but really get at these core things, um, and then studying it just as a as a disease state and trying to study it and put it into experiments and look at endpoints and try to do things from a pure it's just challenging. It's not for the faint of heart. So, um, anybody that goes into it is obviously gets my my my props. but really get at these core things, um, and then studying it just as a as a disease state and trying to study it and put it into experiments and look at endpoints and try to do things from a pure it's just challenging. It's not for the faint of heart. So, um, anybody that goes into it is obviously gets my my my props.
Brandon Li 39:13 Well, certainly, uh, I'd be curious to get your, um, your take here. Certainly, a lot of excitement recently around, uh, developments in, uh, these mood disorders, depression, anxiety, um, with the, uh, with the psychedelic development. Um, curious how how you're how you're thinking about the the kind of latest suites of, um, uh, of candidates here. ious to get your, um, your take here. Certainly, a lot of excitement recently around, uh, developments in, uh, these mood disorders, depression, anxiety, um, with the, uh, with the psychedelic development. Um, curious how how you're how you're thinking about the the kind of latest suites of, um, uh, of candidates here.
Matthew Leoni 39:32 Yeah. In the the depression side, I think, is is interesting. I think there's so the two things that have me interested at least in depression I mean, the psychedelics are interesting. I think for me, the the challenge there is just that the separation of the psychedelics that you saw, they they ran into they're gonna run into the FDA a bunch. But some of the other I think the the the cycloplastogen companies that has sort of removed that, and I I'm thinking, you know, I have colleagues that I that it's companies like and some other ones that, like I think there's something really we're talking about neuro remodeling where you're starting to burgeon on this concept of disease modification. Right? You're remodeling neurons. You're not just interdicting in in a in a receptor or blocking out the endogenous ligand to stop one thing from happening. Like, talking about remodeling neurocircuitry. Um, and it sounds cool. Right? It sounds awesome. It sounds great. But if it it actually starts to prove that they're getting sort of these real big clinical upsides, I think that's gonna be sort of the real first big use case of, you know, disease modification or as close as you can get to it in the psychiatry space. Um, but I think there's a ton going on there. Um, and I think, again, their challenge is going to be one, you know, that separation from all the other side effect psychedelic stuff that we saw, um, Lycos run into and and stuff like that that I think will be challenging and sort of where the true the the psychedelics are gonna run into where I think the psychopathogens, if they can really deliver on, you know, the psychedelic horsepower without the psychedelic part, like, that's where you have a real, uh, I think a real a real a real potential upside. And then I think there's there's other places we see in depression. There's some other, you know, newer targets that I think are just gonna be more incremental, um, in terms of just getting you to places where maybe lower side effects or something you can add to get better effect out of an SSRI. And so, you know, we had some we worked on some of those receptors, and others are working on them. And I I'm thinking about, you know, C port and others that have some cool interesting technologies on drug delivery that are trying to get better. But to me, these are, you know, incremental changes that we have to keep doing. Because in the absence of having truly groundbreaking stuff, we have to keep doing the incremental until we find something that blows it up. Um, and we and we really sort of get these you know, you never get it's never Darwinian that you have these mass explosions. It's always sort of these little tiny changes, but then we hopefully get to sort of a break point and something break changes. So you keep pushing it that way. So I think on the, you know, on the depression side and things like that, the muscarinic were obviously really interesting for us, and I do think there's a lot there. I think it's just still there's a lot to figure out in terms of, you know, potency and kind of what what's the best type of an approach there and agonist and PAM and, um, still again, all of these indications are gonna be plagued with what we talked about in the beginning was Yep. Is is as good as they are, um, you know, to really overcome a lot of these challenges around patient patient access and patient or at least access to new patients and access to, you know, better tools and better measures unless you have this massive effect, which, like, you rarely ever get, you know, which I rarely ever get. Um, it's gonna be challenging to be showing, you know, and convincing of a of a drug of it. And that could be the that's to me that's what scares me with the psychopathic is that they they could be really impactful. But if the effect isn't like like the you know, they're gonna deal with the same issues that the SSR is another with these sort of small effect sizes. And then if they just get chalked up to well, they don't really work all that well. They're not better than SSRI, so nobody's gonna pay for them. So we're not gonna really deal with them. But, like, you're really talking about a really novel mechanism that if you can show the effect, is it, you know, is it just that we're just not able to really sort of capture all the benefit in sort of these rudimentary tools that we're still using, um, but that we have to use? But I think that's the to me, the John. But I think that's really, for me, the like, any of the any of these new candidates that we can get sort of into more. And, um, I'm thinking about too, like, in the depression space and also, right, in the psych in the schizophrenia space, but work that's happening on to understand the neuroinflammatory component. I think that will start to change the landscape. I think we've we've sussed out a lot on sort of the the basics of sort of the normal receptors that are working there and sort of just the how you symptomatically treat these diseases. And you said well, the muscarinic are basically a new approach to an old problem of just, like, let's find a different receptor that was cool and, like, we still can reduce dopamine and we don't get all these dopamine side effects. So, you know, these getting the same effects with fewer side effects is a great approach to sort of address the unmet need of side effects at burning these patients, but sort of really getting the groundbreaking therapy of changing the courses of these diseases and things like that. I think it takes it's gonna take a bit more. Um, and that's where I I wanna see things like, you know, better understanding, better mapping of how neuroinflammation plays a role, and we can kind of cross linking that in with the genetics of some of these disorders. And I think you might getting start getting into some real interesting therapies. But I don't think that's that's not gonna happen next year. Right? I think there's some interesting stuff that's kinda brewing around the edges that'll come along. And I think for now, you're gonna see still a lot of sort of these things that could make impactful changes for people that, you know, maybe have recalcitrant diseases and give them some additional options. Um, you know, like some new some new again, whether it's Parkinson's and sort of the drug that the the the formal cerebellum, now AbbVie drug, they hit the the the tlavanone, which was a target people were trying to get for a long time. They couldn't. We figured out a way to do it. It's gonna add to that armamentarium. It's gonna give them another option if they're failing on certain drugs. So it certainly will help a lot of people, um, but having that big sort of population effect on the disease state, um, when that we're looking for, it's sort of these bigger things that I think are always kind of the holy grail for drug developers. I think, um, you know, we're gonna have to keep plugging away, keep trying to, you know, get better measures, get a sensitive measure, keep pushing the boundaries on kind of, um, what we will and and push new ideas of what what makes up this disease. That's why, again, I like some of the work that I've seen with sort of bringing back the concept of neuroinflammation and and the genetic component into schizophrenia. And how can we sort of multimodally attack this disease both on the, you know, the receptor side with dopamine, but also on what's happening in the trigger from neuroinflammation and and and stuff like that. Um, I think I gotta know. ack the concept of neuroinflammation and and the genetic component into schizophrenia. And how can we sort of multimodally attack this disease both on the, you know, the receptor side with dopamine, but also on what's happening in the trigger from neuroinflammation and and and stuff like that. Um, I think I gotta know.
Brandon Li 45:40 I gotta closer. I I gotta I gotta I gotta ask, um, which three programs are you most closely watching, uh, right now? Are you most excited about?
Matthew Leoni 45:51 Yeah. Put me on the spot, um, with three programs, am I most closely watching? I mean, just out of in see, you're gonna get biased, like, just out of interest. Like, I'm I'm watching the Muscarinic space just because I came from it and because I came off of a failure. Um, and it wasn't a failure of, I think, of execute I again, I think it's and so I wanna I'm really interested to see because I do think there's a lot of value there incrementally, um, of where we're going. Um, so I'm watching, I think, across those different programs, are you looking at new more? Are you looking at neurocrime? Um, looking to see what AbbVie can do and where others, I think there's plenty of interest in the space, but can can they evolve that? So I think in the near term, I'm looking to see. So I think that will have a lot of benefit to patients. Um, and then in the like, on the other side of it, I'm kind of I'm I'm more interested in, I think, on the bizarre the Parkinson's disease modification stuff, I'm still sort of hopeful around alpha synuclein. And I'm looking at some of the, um, some of the programs that are a little a little get more isotactic in looking at the inflammasome. And so there's a couple of different programs that are out there that are focusing in on on the, uh, inflammasome components that are they're mixing everything with, like, GLP one now and stuff like that. But there's, I think, a couple of different companies that I'm I'm kinda like, um, Ceravance and some other ones that have some interesting stuff that I think are really looking at targets that are getting again a bit closer into the than the the mode of more disease modifying or changing sort of the way the disease is processed as opposed to just interdicting at the receptor level. So I think that's probably where I'm most most interested right now is kind of making you looking to see what happens with with the the muscarinic, etcetera, because I think they there's still a lot of ground to cover there. Um, some of the other stuff, I mean, I'm I'm not as, like I think that's it's kind of, like, interesting, but it's not it's just kinda, like, old kinda rehashing of things and have they think in, like, the depression space and stuff like that. So I think think, um, that's probably at least in the in the neuro the neurospace right now, that's kinda what I'm kinda what I'm watching. nk that's it's kind of, like, interesting, but it's not it's just kinda, like, old kinda rehashing of things and have they think in, like, the depression space and stuff like that. So I think think, um, that's probably at least in the in the neuro the neurospace right now, that's kinda what I'm kinda what I'm watching.
Brandon Li 47:55 Gotcha. So and I've already mapped that to kind of, like, condition areas. It's like like the work currently being done in schizophrenia, um, some of the interesting work, um, potentially over in Parkinson's, and then, uh, a lot of the rest of the field, you're like, you're not as closely watching or or, um, andon Li: Gotcha. So and I've already mapped that to kind of, like, condition areas. It's like like the work currently being done in schizophrenia, um, some of the interesting work, um, potentially over in Parkinson's, and then, uh, a lot of the rest of the field, you're like, you're not as closely watching or or, um,
Matthew Leoni 48:13 um, uh, it's fine. I mean, look, in neuro, there's there's tons and tons of rare Yeah. Things to be looking at on the I mean, both on the on the on the gene therapy side of the disease modifying side that that, like, you couldn't watch all of them if you wanted to. And I'm not a an expert in in the rare disorder. So, I mean, I think there's a ton of things for specific people that if they have something in their family or they have something that that they just there's plenty of places to have the hopeful in terms of these very small disorders that lend themselves to a very specific therapy like a gene modification or something like spinal muscular atrophy and and we have places where some of those companies have have made a lot of ground. And I think you still see a lot of people attacking that. You know? You still see where a lot of the, um, the the plasma based therapies that are they're they're working on. Like, they're gonna make they're gonna make up ground, and they're gonna get better and better technologies and stuff like that. I think, again, for these the the stuff I like to watch is the the larger these larger sort of the large big disease burdens of, like, psychiatric illness and the big neurodegenerative k like Parkinson's and Alzheimer's and stuff like that, um, that I'm kinda watching and hoping to see, like, in Alzheimer's, I'm just seeing bet like, how can we better improve on beta amyloid or what got approved is kinda chasing that they're still still chasing that dragon. Um, so I'm hoping to see I'm kind of watching, and I'm hopeful for some of these companies that are maybe sort of a going at it in a new way, and we can get better with terms of, like, you know, genetic targets and more thing over. But I'm seeing a a lot of the interest rightly so, a lot of the investor interest goes towards, hey. They finally figured out a way to get some of the astronauts approved, and so let's let's now innovate on that and incrementally make them better and keep going. Like, that's generally what happens in the industry. It's like you find some at work and then you like, everybody incrementally improves on it because it's sort of a known thing you can keep doing, um, which is easier to do than kind of forging a new pathway. Um, but, again, I think there's there's a closer we're probably closer to something meaningful, you know, either genetic based or others in Parkinson's and movement disorders than we are in the dementia space. So I I tend to watch that pretty closely in terms of, um, and all and all the you know, even in the smaller rarer stuff, but just in the larger, um, you know, sort of, like, what what they're looking at. So one of the like, for example, in the parking space, I'm looking at, um, like, the the GBA mute mutant mutation drugs. Um, so those are really interesting. So, like, GBA Parkinson's disease, it's not idiopathic Parkinson's, but it is it's caused we you know, it's been identified as the GBA mutation causes a Parkinson like syndrome. And so there's they're targeting that. And so it's you're getting into sort of disease modification at that level. The Lark two programs were the same way. It's not treating everybody, but Parkinson's is such an sort of a heterodimer of a disease state where there's lots of different groups in there. And then, like, if we can come at them and sort of start piecing them apart and taking them down, um, I think that's where a lot of the interest will be. So, yeah, I I watched Parkinson's did pretty closely. Parkinson's is such an sort of a heterodimer of a disease state where there's lots of different groups in there. And then, like, if we can come at them and sort of start piecing them apart and taking them down, um, I think that's where a lot of the interest will be. So, yeah, I I watched Parkinson's did pretty closely.
Brandon Li 51:05 Yeah. Fascinating. Um, okay. So, uh, I know that we're, uh, we're getting close to the, the end of our time here. Um, Matt, if you had a magic wand to change anything about how drug development is, uh, is done today in neuro, um, what would you change in life? hed Parkinson's did pretty closely. Yeah. Fascinating. Um, okay. So, uh, I know that we're, uh, we're getting close to the, the end of our time here. Um, Matt, if you had a magic wand to change anything about how drug development is, uh, is done today in neuro, um, what would you change in life?
Matthew Leoni 51:20 Oh, man. That's a great question, man. Um, I mean, I was like, as a drug developer, you're always complaining about the speed at which you can't you know, the slowness and from a regulatory perspective. But I don't really get to too much because it's there for a reason. It's there to make sure that, you know, we're we're meeting a burden of proof. Um, so I I I wouldn't wave away to say, like, it'd be great if we didn't have all these regulations, and we could just, like, really kind of because I think that's a way for, like, people to get hurt. So I don't think it's way but I think it's it's a there's a lot of limitations in sort of what we can explore, um, just the way the sort of, like, the investment in the financial system is set up for us, um, and what you can what you can and can't do. And, again, um, that all the incentive is around, like, what we just talked about, like, face what works, chase what you know is has a high probability success, so it will return profit. Because it's a for profit industry. And that's, I think, the if I could wave sort of this one, it's sort of to change that notion of you've got academia and academic research, which is really for the science of it, and then you've got pharma. And we make some great innovations, and there's lots of cross between that or whatever. But at the end of the day, pharma is about, you know, returning investment for, you know, helping patients, but also returning investment for sure. You have shareholders. You have all these things, and you have financial constraints. And so because of those limitations, you know, we're not doing stuff based on grants and we can afford to fail at a lot of things. Um, I think it just restricts us in our thinking and restricts us, and it and it forces you into a mindset of, you know, being more conservative, more following following the path that's been set for you, following the path of, like, least resistance, following the path of, like, um, what we you know, like, again, what we said around, uh, something that's known and it works. Like, I wanna make sure it's successful, and I wanna make so this is the easy way to do it. But that may be not the best way. And and this is that's not what breeds the most innovation and the most change, and I think I think we it would be if I could wave it and just make it a whole different dynamic, and I couldn't because this is just the nature of the piece that we're in. And it and it does it. We did we're the it's the best environment in the world for drug development, and we make the best because of all those incentives and, you know, people that realize the drug industry and stuff for that. Like, the reason we have all these therapies because of the way it's set up. But even then, when you see sort of when you're inside pharma and you see the mentality in drug development and you see how all these different stakeholders that you have to deal with and sort of what we're incentivized or how we're incentivized to behave and think, um, to sort of develop drugs and what we're to do when we're posting versus completely, you know, go the way I think, like, you know, Steve Jobs was at Avenue. It's like, send a whole group off and just think about all new shit. And it's just, you know, like, think about everything crazy and do all this kind of stuff. Um, there's not a ton of incentive. There's maybe the optics of the we wanna do that, but there's really not. And I think that's what I would change because I think that's probably what limits us to more just in these incremental benefits over time, um, that if we did more of that, you'd see more losses and you'd see more, you know, even more failures and more things like that. But I think it would it would put us on a pathway to faster sort of large explosion and sort of groundbreaking changes. You know? ts us to more just in these incremental benefits over time, um, that if we did more of that, you'd see more losses and you'd see more, you know, even more failures and more things like that. But I think it would it would put us on a pathway to faster sort of large explosion and sort of groundbreaking changes. You know?
Brandon Li 54:43 Yeah. Um,
Matthew Leoni 54:43 so I wish we had that I wish we had that luxury, but we don't. We we can't make the industry like that. The industry is what it is, and it's and it's
Brandon Li 54:49 It has to work the way it works.
Matthew Leoni 54:50 And so we make we make incremental changes, and we make incremental changes. And then, hopefully, the science catches up at some point in in something and the the two merge and there's there's a flash point, and then we have a big, uh, a big outcome and stuff. And we've seen it happen. I just wish it happened faster.
Brandon Li 55:05 Yeah. Well, I mean, maybe there's some enterprising entrepreneurs listening to this who thinks, well, maybe there's a different model that I can, uh, I could think through that, uh, then maybe I'd
Matthew Leoni 55:13 love to see it. I I I there's been some there's, you know, the the VANT model, you know, like, Vivac is bottled before, and, like, some of these other things about how you approach it was starting to sort of taste that. Yeah. But right now, the the landscape that we have of sort of just the large pharma model, you know, looks around for stuff, and then the the startups, you know, I mean, you know, we we we get money. We take the risk. We we figure something out, and we but we still try to limit all that risk, and then we get bought up. Like, that model, I think it's still sort of just driving this kinda incremental stuff that we if we could think of something different. But Yeah. That's for another day.
Brandon Li 55:46 Risk is risk adjusted risk adjusted, um, return is a, um, the well, it's a it's an important constraint, but it's, uh, it is a constraint on, uh, maybe a some a local maxima.
Matthew Leoni 55:59 Yeah. It is. It is.
Brandon Li 56:00 Yeah. Well, Matt, this has been a, uh, fun conversation. I appreciate you taking the time and, um, taking all the detours with me here.
Matthew Leoni 56:07 Awesome. Yeah. No. It's been been a lot of fun, Brandon. Thanks. Anytime.